Bronnen:
- Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study. Arthritis Rheumatol. 2019 Mar 8.